Elliptinium (BioDeep_00000844125)
代谢物信息卡片
Elliptinium
化学式: C18H17N2O+ (277.1341)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC1=C2C=C[N+](=CC2=C(C3=C1NC4=C3C=C(C=C4)O)C)C
InChI: InChI=1S/C18H16N2O/c1-10-15-9-20(3)7-6-13(15)11(2)18-17(10)14-8-12(21)4-5-16(14)19-18/h4-9,21H,1-3H3/p+1
描述信息
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
D000970 - Antineoplastic Agents > D000972 - Antineoplastic Agents, Phytogenic > D004611 - Ellipticines
C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C1748 - Topoisomerase Inhibitor
C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C2842 - DNA Binding Agent
D019995 - Laboratory Chemicals > D007202 - Indicators and Reagents > D007364 - Intercalating Agents
同义名列表
1 个代谢物同义名
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
| 亚细胞结构定位 | 关联基因列表 |
|---|
文献列表
- Astha Varma, Harish Padh, Neeta Shrivastava. Andrographolide: a new plant-derived antineoplastic entity on horizon.
Evidence-based complementary and alternative medicine : eCAM.
2011; 2011(?):815390. doi:
10.1093/ecam/nep135. [PMID: 19752167] - Yi-ling Lu, Ben-xia Yang, Zong-ning Yin. Immunotargeting of collagenase on thrombus.
International journal of nanomedicine.
2010 Nov; 5(?):973-82. doi:
10.2147/ijn.s13904. [PMID: 21187949] - M Samadi-Baboli, G Favre, P Canal, G Soula. Low density lipoprotein for cytotoxic drug targeting: improved activity of elliptinium derivative against B16 melanoma in mice.
British journal of cancer.
1993 Aug; 68(2):319-26. doi:
10.1038/bjc.1993.335. [PMID: 8347487] - D Lemeteil, F Roussel, L Favennec, J J Ballet, P Brasseur. Assessment of candidate anticryptosporidial agents in an immunosuppressed rat model.
The Journal of infectious diseases.
1993 Mar; 167(3):766-8. doi:
10.1093/infdis/167.3.766. [PMID: 8440946] - N Thomas, G Raguenez-Viotte, M Dieber-Rotheneder, H Esterbauer, J P Fillastre. Time course study of lipid peroxidation induced by N2-methyl-9-hydroxyellipticinium acetate or celiptium in rat renal cortex.
Pharmacology & toxicology.
1991 Aug; 69(2):112-6. doi:
10.1111/j.1600-0773.1991.tb01282.x. [PMID: 1775430] - N Thomas, B Moulin, G Raguenez-Viotte, J P Fillastre. Nephrotoxicity of an ellipticine derivative (N2-methyl-9-hydroxyellipticinium acetate) in rat: a defect of urinary concentrating ability.
Renal failure.
1991; 13(4):243-51. doi:
10.3109/08860229109022160. [PMID: 1780492] - G Raguenez-Viotte, N Thomas, J P Fillastre. Subcellular localization of celiptium-induced peroxidative damage in rat renal cortex.
Archives of toxicology.
1991; 65(3):244-51. doi:
10.1007/bf02307316. [PMID: 2053851] - G Raguenez-Viotte, M Dieber-Rotheneder, C Dadoun, J P Fillastre, H Esterbauer. Evidence for 4-hydroxyalkenals in rat renal cortex peroxidized by N2-methyl-9-hydroxyellipticinium acetate or Celiptium.
Biochimica et biophysica acta.
1990 Oct; 1046(3):294-300. doi:
10.1016/0005-2760(90)90244-r. [PMID: 2145981] - C Dadoun, G Raguenez-Viotte. Celiptium-induced nephrotoxicity and lipid peroxidation in rat renal cortex.
Cancer chemotherapy and pharmacology.
1990; 27(3):178-86. doi:
10.1007/bf00685710. [PMID: 2265453] - G Raguenez-Viotte, J P Fillastre. Bleb formation in the renal epithelial cell line LLC-PK1 exposed to N2-methyl-9-hydroxyellipticinium acetate (celiptium).
International journal of tissue reactions.
1990; 12(6):347-51. doi:
NULL. [PMID: 2102898] - A M Sautereau, M Betermier, A Altibelli, J F Tocanne. Adsorption of the cationic antitumoral drug celiptium to phosphatidylglycerol in membrane model systems. Effect on membrane electrical properties.
Biochimica et biophysica acta.
1989 Jan; 978(2):276-82. doi:
10.1016/0005-2736(89)90125-9. [PMID: 2914142] - M Maftouh, C Picard, H Roché. Pharmacokinetic study of 14C-radiolabelled elliptinium acetate in patients with metastatic breast cancer.
Arzneimittel-Forschung.
1988 Oct; 38(10):1513-5. doi:
NULL. [PMID: 3196392] - K Nicolay, A M Sautereau, J F Tocanne, R Brasseur, P Huart, J M Ruysschaert, B de Kruijff. A comparative model membrane study on structural effects of membrane-active positively charged anti-tumor drugs.
Biochimica et biophysica acta.
1988 May; 940(2):197-208. doi:
10.1016/0005-2736(88)90195-2. [PMID: 3163502] - Y Braham, G Meunier, B Meunier. The rat biliary and urinary metabolism of the N6-methylated derivative of elliptinium acetate, and antitumor agent.
Drug metabolism and disposition: the biological fate of chemicals.
1988 Mar; 16(2):316-21. doi:
NULL. [PMID: 2898353] - A Gouyette. Synthesis of deuterium-labelled elliptinium and its use in metabolic studies.
Biomedical & environmental mass spectrometry.
1988 Mar; 15(5):243-7. doi:
10.1002/bms.1200150502. [PMID: 3365494] - G Raguenez-Viotte, C Dadoun, P Buchet, T Ducastelle, J P Fillastre. Renal toxicity of the antitumor drug N2-methyl-9-hydroxyellipticinium acetate in the Wistar rat.
Archives of toxicology.
1988; 61(4):292-7. doi:
10.1007/bf00364852. [PMID: 3377684] - J P Droz, C Theodore, M Ghosn, H Lupera, G Piot, A De Forges, M Klink, J Rouesse, J L Amiel. Twelve-year experience with chemotherapy in adult metastatic renal cell carcinoma at the Institut Gustave-Roussy.
Seminars in surgical oncology.
1988; 4(2):97-9. doi:
NULL. [PMID: 3393780] - G Piot, J P Droz, C Theodore, M Ghosn, J Rouëssé, J L Amiel. Phase II trial with high-dose elliptinium acetate in metastatic renal cell carcinoma.
Oncology.
1988; 45(5):371-2. doi:
10.1159/000226643. [PMID: 3412745] - C L Arteaga, D L Kisner, A Goodman, D D von Hoff. Elliptinium, a DNA intercalating agent with broad antitumor activity in a human tumor cloning system.
European journal of cancer & clinical oncology.
1987 Nov; 23(11):1621-6. doi:
10.1016/0277-5379(87)90440-8. [PMID: 3428332] - A Gouyette, E Voisin, C Auclair, C Paoletti. Isolation and characterization of the glutathione-elliptinium conjugate in human urine.
Anticancer research.
1987 Jul; 7(4B):823-7. doi:
NULL. [PMID: 3674767] - A M Sautereau, S Cros, J F Tocanne. Inhibition of tumor cell growth in vitro and in vivo by 2-methyl 9-hydroxyellipticinium entrapped within phospholipid vesicles.
Biopharmaceutics & drug disposition.
1986 Jul; 7(4):357-71. doi:
10.1002/bdd.2510070406. [PMID: 3768491] - G F Alberici, R Fellous, J M Bidart, F Troalen, J M Mondesir, A Goodman, D H Ho, C Bohuon. Human antibodies to the antineoplastic drug elliptinium: characterization and structure-activity relationships.
The Journal of allergy and clinical immunology.
1986 Apr; 77(4):624-30. doi:
10.1016/0091-6749(86)90356-8. [PMID: 2420854] - A Eschalier, J Lavarenne, C Burtin, P Tounissou. Acute hemodynamic effects of an antitumoral agent: elliptinium. Involvement of histamine release.
Agents and actions.
1986 Mar; 17(5-6):441-8. doi:
10.1007/bf01965511. [PMID: 2422901] - Y Pommier, R E Schwartz, L A Zwelling, D Kerrigan, M R Mattern, J Y Charcosset, A Jacquemin-Sablon, K W Kohn. Reduced formation of protein-associated DNA strand breaks in Chinese hamster cells resistant to topoisomerase II inhibitors.
Cancer research.
1986 Feb; 46(2):611-6. doi:
NULL. [PMID: 3000581] - D C Doll, R B Weiss. Hemolytic anemia associated with antineoplastic agents.
Cancer treatment reports.
1985 Jul; 69(7-8):777-82. doi:
NULL. [PMID: 3160460] - P Caillé, J M Mondesir, J P Droz, P Kerbrat, A Goodman, J P Ducret, C Theodore, M Spielman, J Rouëssé, J L Amiel. Phase II trial of elliptinium in advanced renal cell carcinoma.
Cancer treatment reports.
1985 Jul; 69(7-8):901-2. doi:
NULL. [PMID: 4016798] - C N Sternberg, A Yagoda, E Casper, M Scoppetuolo, H I Scher. Phase II trial of elliptinium in advanced renal cell carcinoma and carcinoma of the breast.
Anticancer research.
1985 Jul; 5(4):415-7. doi:
NULL. [PMID: 4037737] - J G Rouësse, T Le Chevalier, P Caille, J M Mondesir, H Sancho-Garnier, F May-Levin, M Spielmann, R De Jager, J L Amiel. Phase II study of elliptinium in advanced breast cancer.
Cancer treatment reports.
1985 Jun; 69(6):707-8. doi:
NULL. [PMID: 4016774] - L Lempereur, A M Sautereau, J F Tocanne, G Laneelle. Ellipticine derivatives interacting with model membranes. Influence of quaternarization of nitrogen-2.
Biochemical pharmacology.
1984 Aug; 33(15):2499-503. doi:
10.1016/0006-2952(84)90724-x. [PMID: 6466364] - J L Amiel, J Rouessé, J P Droz, P Caille, J P Travagli, C Théodore, T Le Chevalier, J P Ducret, M Bidart, H S Garnier. [Treatment of metastatic renal cancer in adults with elliptinium acetate].
Presse medicale (Paris, France : 1983).
1984 Jun; 13(25):1555-7. doi:
NULL. [PMID: 6234539] - H Nagasawa, M Homma, H Namiki, K Niki. Inhibition by hydroxy-N-methyl elliptinium of precancerous mammary hyperplastic alveolar nodule formation in mice.
European journal of cancer & clinical oncology.
1984 Feb; 20(2):273-6. doi:
10.1016/0277-5379(84)90195-0. [PMID: 6538491] - J P Ryckelynck, J F Heron, P Juret, E De Ranieri, P Herlin, A Hardouin, J Y Le Talaer. [Renal toxicity of 9-hydroxy-2-methylellipticinium].
Presse medicale (Paris, France : 1983).
1984 Jan; 13(2):104. doi:
NULL. [PMID: 6229731] - J P Ryckelynck, J F Heron, P Juret, P Schneider, P Herlin, E De Ranieri, A Hardouin, J Peny, J Y Le Talaer. [Renal toxicity of 9-hydroxy-2-methyl-ellipticinium].
Nephrologie.
1984; 5(2):59-63. doi:
NULL. [PMID: 6483073] - B Monsarrat, M Maftouh, G Meunier, B Dugué, J Bernadou, J P Armand, C Picard-Fraire, B Meunier, C Paoletti. Human and rat urinary metabolites of the antitumor drug Celiptium (N2-methyl-9-hydroxyellipticinium acetate, NSC 264137). Identification of cysteine conjugates supporting the 'biooxidative alkylation' hypothesis.
Biochemical pharmacology.
1983 Dec; 32(24):3887-90. doi:
10.1016/0006-2952(83)90171-5. [PMID: 6661266] - C Auclair, B Meunier, C Paoletti. Peroxidase-catalysed covalent binding of the antitumor drug 2N-methyl-9-hydroxy-ellipticine to proteins.
Biochemical pharmacology.
1983 Dec; 32(24):3883-6. doi:
10.1016/0006-2952(83)90170-3. [PMID: 6661265] - A Gouyette, D Huertas, J P Droz, J Rouesse, J L Amiel. Pharmacokinetics of 2-methyl-9-hydroxyellipticinium acetate (NSC-264137) in cancer patients (phase I study).
European journal of cancer & clinical oncology.
1982 Dec; 18(12):1285-92. doi:
10.1016/0277-5379(82)90130-4. [PMID: 6891926] - P Juret, J F Heron, J E Couette, T Delozier, J Y Le Talaer. Hydroxy-9-methyl-2-ellipticinium for osseous metastases from breast cancer: a 5-year experience.
Cancer treatment reports.
1982 Nov; 66(11):1909-16. doi:
NULL. [PMID: 7139636] - J Rouesse, T Tursz, T Le Chevalier, D Huertas, J L Amiel, G Brule, B Callet, J P Droz, P M Voisin, H Sancho-Garnier, J B Le Pecq, C Paoletti. [N-Methyl-9 hydroxy-ellipticine (NSC 264-137) in the treatment of malignant metastases. Preliminary results (author's transl)].
La Nouvelle presse medicale.
1981 May; 10(24):1997-9. doi:
. [PMID: 7255136] - C Auclair, C Paoletti. Bioactivation of the antitumor drugs 9-hydroxyellipticine and derivatives by a peroxidase-hydrogen peroxide system.
Journal of medicinal chemistry.
1981 Mar; 24(3):289-95. doi:
10.1021/jm00135a010. [PMID: 7265115] - A M Criel, M Hidajat, A Clarysse, R L Verwilghen. Drug dependent red cell antibodies and intravascular haemolysis occurring in patients treated with 9 hydroxy-methyl-ellipticinium.
British journal of haematology.
1980 Dec; 46(4):549-56. doi:
10.1111/j.1365-2141.1980.tb06011.x. [PMID: 7437333] - N Van-Bac, C Moisand, A Gouyette, G Muzard, N Dat-Xuong, J B Le Pecq, C Paoletti. Metabolism and disposition studies of 9-hydroxyellipticine and 2-methyl-9-hydroxyellipticinium acetate in animals.
Cancer treatment reports.
1980 Aug; 64(8-9):879-87. doi:
NULL. [PMID: 7448826]
